Bayshore Pharmaceuticals USA, headquartered in Parsippany, New Jersey, was acquired by Centaur Pharmaceuticals in 2026, accelerating its U.S. growth and backing it with a globally seasoned manufacturer committed to delivering quality medicines to patients who need them.

As a subsidiary of Mumbai-based Centaur, Bayshore taps 40+ years of formulation and API manufacturing expertise, including three US-FDA audited facilities in India, spanning Benzodiazepine, CNS, Cardiovascular, Antithrombotic, and Anti-diabetic therapies that support patients managing complex, everyday health conditions.

Bayshore builds reliable U.S. supply partnerships through B2B licensing and distributor relationships, growing its portfolio of approved ANDAs and First-to-File formulations so patients get affordable access to the medicines they depend on.